Adam Szaronos is the CEO and board member of Iantrek, Inc., a bio-interventional medicine company. With a proven track record of building commercial-stage businesses and leading innovations to market, ...

Most recently, Mr. Szaronos served as CEO and President of Trukera Medical, where he led a comprehensive turnaround and repositioning of the organization, resulting in its successful acquisition ...

Trukera, which counts a team of 15 sales representatives, is getting a significant boost with the acquisition, joining Bausch + Lomb’s 13,000 global employees. “They can put the scale behind the ...

Atkins pointed to the InflammaDry test and new ScoutPro portable osmolarity measuring device from Trukera Medical (formerly TearLab) for accurate and actionable data. "For me, the future is about ...

Trukera Medical has undergone significant change in the past three years since investment firm Accelmed Partners acquired the company. With new owners, as well as management and board members, it is ...

Additionally, from 2006 to 2017, he served as the President and CEO of Radiancy Inc., a subsidiary of PhotoMedex. He is also on the Board of Directors of Trukera Medical, formally TearLab Corporation.

Etiology and Pathophysiology of DED. DED is a multifactorial disease of the ocular surface that may arise consequent to disrupted homeostasis of the ocular tear film. 1,11,19 When ocular surface ...

BOARD WORK: Executive chairman for Neurotech Pharmaceuticals, a retinal implant company; executive chair at Centricity Vision and Trukera; and serves on the boards of LensGen and Iantrek. Also on ...

NEW YORK — In this Healio Video Perspective at OSN New York, Carey Kelson and John Steenbakkers discuss Trukera Medical’s recently launched ScoutPro osmolarity system.

At Trukera Medical, we've recently rebranded our organization historically founded as TearLab, a one-product company focused on in vitro diagnostics to help advance corneal health and decision making.